| Item Type | Name |
|
Academic Article
|
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
|
|
Academic Article
|
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
|
|
Academic Article
|
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.
|
|
Concept
|
Cell Line, Tumor
|
|
Academic Article
|
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
|
|
Academic Article
|
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
|
|
Academic Article
|
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
|
|
Academic Article
|
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.
|
|
Academic Article
|
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
|
|
Academic Article
|
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.
|
|
Academic Article
|
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
|
|
Academic Article
|
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
|
|
Academic Article
|
An integrin ?3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
|
|
Academic Article
|
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
|
|
Academic Article
|
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
|
|
Academic Article
|
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.
|
|
Academic Article
|
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
|
|
Academic Article
|
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
|
|
Academic Article
|
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
|
|
Academic Article
|
The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
|
|
Academic Article
|
C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.
|
|
Academic Article
|
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
|
|
Academic Article
|
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
|
|
Academic Article
|
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
|
|
Academic Article
|
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
|
|
Academic Article
|
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
|
|
Academic Article
|
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
|
|
Academic Article
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
|
Academic Article
|
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
|
|
Academic Article
|
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
|
|
Academic Article
|
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy.
|
|
Academic Article
|
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
|
|
Academic Article
|
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
|
|
Academic Article
|
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
|
|
Academic Article
|
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
|
|
Academic Article
|
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
|
|
Academic Article
|
Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer.
|
|
Academic Article
|
Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.
|
|
Academic Article
|
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
|
|
Academic Article
|
A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.
|
|
Academic Article
|
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
|
|
Academic Article
|
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
|
|
Academic Article
|
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
|
|
Academic Article
|
TGF?1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.
|
|
Academic Article
|
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer.
|
|
Academic Article
|
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
|
|
Academic Article
|
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
|
|
Academic Article
|
Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
|
|
Academic Article
|
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
|
|
Academic Article
|
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
|
|
Academic Article
|
Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.
|
|
Academic Article
|
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
|
|
Academic Article
|
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
|
|
Academic Article
|
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
|
|
Academic Article
|
AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
|
|
Academic Article
|
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.
|
|
Academic Article
|
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
|
|
Academic Article
|
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
|
|
Academic Article
|
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
|
|
Academic Article
|
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
|
|
Academic Article
|
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
|
|
Academic Article
|
Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
|
|
Academic Article
|
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.
|
|
Academic Article
|
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ?-blockers.
|
|
Academic Article
|
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
|
|
Academic Article
|
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
|
|
Academic Article
|
eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.
|
|
Academic Article
|
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
|
|
Academic Article
|
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
|
|
Academic Article
|
An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.
|
|
Academic Article
|
miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer.
|
|
Academic Article
|
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells.
|
|
Academic Article
|
Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy.
|
|
Academic Article
|
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
|
|
Academic Article
|
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
|
|
Academic Article
|
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
|
|
Academic Article
|
Altered Regulation of HIF-1a in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
|
|
Academic Article
|
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
|
|
Academic Article
|
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
|
|
Academic Article
|
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.
|
|
Academic Article
|
The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics.
|
|
Academic Article
|
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
|
|
Academic Article
|
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
|
|
Academic Article
|
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner.
|